Designs to Detect Disease Modification

Michael P. McDermott ()
Additional contact information
Michael P. McDermott: University of Rochester Medical Center, Department of Biostatistics and Computational Biology

Chapter 64 in Principles and Practice of Clinical Trials, 2022, pp 1199-1218 from Springer

Abstract: Abstract Designing a trial to determine whether or not an intervention has modified the underlying course of the disease is straightforward for certain conditions, such as cancer, in which it is possible to directly measure the disease course. For many other diseases, the disease course is latent, and one must rely on indirect measures such as clinical symptoms to quantify the effects of interventions. In this case, it is difficult with conventional trial designs to determine the extent to which the treatment is modifying the disease course as opposed to merely alleviating the symptoms of the disease. This distinction has become critically important in the study of treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, but it applies to many other diseases as well. This chapter discusses proposed strategies for trial design to attempt to distinguish between the disease-modifying and symptomatic effects of a treatment in diseases with a latent disease course. Two-period designs, such as the withdrawal design and the delayed start design, are being used for this purpose, most commonly in neurodegenerative disease. In these designs, the first period involves a standard randomization of participants to active and placebo treatments. In the second period, those in the active treatment group are switched to placebo (withdrawal design), or those in the placebo group are switched to active treatment (delayed start design). These designs are reviewed in detail in terms of their underlying assumptions, limitations, and strategies for statistical analysis.

Keywords: Two-period design; Withdrawal design; Delayed start design; Disease-modifying effect; Symptomatic effect; Alzheimer’s disease; Parkinson’s disease; Missing data; Noninferiority (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_93

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_93

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().